Dong Sung Bio Pharm.Co.,Ltd.
KRX:002210.KS
4490 (KRW) • At close November 1, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 88,593.589 | 93,328.195 | 84,407.658 | 87,799.927 | 86,536.755 | 91,912.686 | 82,385.234 | 79,720.855 | 74,660.371 | 73,157.942 | 75,175.284 | 84,581.021 | 78,442.098 | 71,926.026 | 68,724.16 | 62,231.434 | 60,319.47 |
| Cost of Revenue
| 47,943.944 | 51,272.755 | 50,864.013 | 53,650.704 | 53,460.249 | 56,718.177 | 46,281.59 | 42,624.9 | 38,182.432 | 37,893.893 | 36,210.899 | 42,056.709 | 33,020.846 | 31,919.446 | 27,614.751 | 25,271.393 | 23,739.752 |
| Gross Profit
| 40,649.645 | 42,055.44 | 33,543.645 | 34,149.223 | 33,076.507 | 35,194.508 | 36,103.644 | 37,095.955 | 36,477.94 | 35,264.049 | 38,964.386 | 42,524.312 | 45,421.251 | 40,006.58 | 41,109.409 | 36,960.041 | 36,579.718 |
| Gross Profit Ratio
| 0.459 | 0.451 | 0.397 | 0.389 | 0.382 | 0.383 | 0.438 | 0.465 | 0.489 | 0.482 | 0.518 | 0.503 | 0.579 | 0.556 | 0.598 | 0.594 | 0.606 |
| Reseach & Development Expenses
| 4,169.119 | 4,115.806 | 3,395.328 | 3,373.318 | 3,104.422 | 3,004.217 | 2,460.263 | 2,349.488 | 2,481.539 | 2,478.345 | 2,458.153 | 2,195.74 | 377.325 | 193.099 | 332.145 | 252.34 | 169.715 |
| General & Administrative Expenses
| 1,894.014 | 1,833.592 | 1,703.227 | 1,612.685 | 1,927.829 | 1,780.408 | 3,086.554 | 3,132.333 | 3,263.367 | 2,809.116 | 2,827.912 | 2,238.129 | 3,168.721 | 3,222.804 | 3,554.198 | 4,325.936 | 3,132.029 |
| Selling & Marketing Expenses
| 24,762.639 | 27,003.02 | 21,380 | 21,838.337 | 21,754.161 | 19,370.143 | 18,002.879 | 19,469.608 | 19,765.689 | 19,841.783 | 24,182.794 | 25,459.287 | 25,434.059 | 25,871.811 | 24,975.26 | 20,639.841 | 20,212.138 |
| SG&A
| 35,663.127 | 28,836.612 | 23,083.227 | 23,451.022 | 23,681.99 | 21,150.551 | 21,089.434 | 22,601.94 | 23,029.057 | 22,650.899 | 27,010.706 | 27,697.416 | 28,602.78 | 29,094.615 | 28,529.458 | 24,965.777 | 23,344.167 |
| Other Expenses
| -220.996 | 12,200.008 | 12,364.138 | 10,995.656 | 13,821.852 | 243.471 | 327.556 | 796.937 | 479.589 | -977.716 | 420.238 | 1,340.872 | 494.887 | -618.704 | 372.308 | 202.595 | 206.5 |
| Operating Expenses
| 40,053.242 | 45,152.425 | 38,842.693 | 37,819.996 | 40,608.264 | 37,001.766 | 35,148.51 | 39,385.573 | 35,281.041 | 37,094.835 | 40,931.373 | 39,271.254 | 42,313.586 | 43,152.754 | 39,979.461 | 35,352.165 | 34,927.954 |
| Operating Income
| 596.403 | -2,041.798 | -5,299.049 | -3,670.773 | -7,531.758 | -1,807.258 | 955.133 | -2,289.619 | 1,196.898 | -1,830.786 | -1,966.988 | 3,253.058 | 3,595.243 | -3,146.177 | 1,129.949 | 1,607.877 | 1,651.763 |
| Operating Income Ratio
| 0.007 | -0.022 | -0.063 | -0.042 | -0.087 | -0.02 | 0.012 | -0.029 | 0.016 | -0.025 | -0.026 | 0.038 | 0.046 | -0.044 | 0.016 | 0.026 | 0.027 |
| Total Other Income Expenses Net
| -1,462.289 | 191.196 | 919.708 | -7,135.112 | -1,233.787 | -4,885.822 | -1,521.386 | -253.435 | -452.818 | -1,164.472 | -1,147.946 | 338.806 | -1,359.068 | -1,905.081 | -453.954 | 3,628.567 | 1,819.78 |
| Income Before Tax
| -865.886 | -1,850.602 | -4,379.341 | -10,805.885 | -8,765.545 | -6,693.079 | -566.253 | -2,543.054 | 744.08 | -2,995.258 | -3,114.933 | 3,591.864 | 1,748.597 | -5,051.255 | 675.994 | 5,236.443 | 3,471.544 |
| Income Before Tax Ratio
| -0.01 | -0.02 | -0.052 | -0.123 | -0.101 | -0.073 | -0.007 | -0.032 | 0.01 | -0.041 | -0.041 | 0.042 | 0.022 | -0.07 | 0.01 | 0.084 | 0.058 |
| Income Tax Expense
| 1,208.024 | 271.068 | -66.508 | 3,273.253 | -380.341 | -948.522 | -367.989 | -882.61 | 289.242 | 7,951.692 | -1,126.705 | 399.777 | 47.503 | 2,886.089 | 107.563 | 1,579.826 | 815.591 |
| Net Income
| -2,073.91 | -2,121.67 | -4,312.832 | -14,079.138 | -8,385.205 | -5,744.558 | -198.264 | -1,660.443 | 454.838 | -10,946.95 | -1,988.229 | 3,192.088 | 1,701.094 | -7,937.344 | 568.431 | 3,656.617 | 2,655.952 |
| Net Income Ratio
| -0.023 | -0.023 | -0.051 | -0.16 | -0.097 | -0.063 | -0.002 | -0.021 | 0.006 | -0.15 | -0.026 | 0.038 | 0.022 | -0.11 | 0.008 | 0.059 | 0.044 |
| EPS
| -90.7 | -92.23 | -184.52 | -599.87 | -363.57 | -293 | -10 | -83.29 | 23 | -589 | -110 | 181 | 96 | -441 | 31 | 201 | 152.6 |
| EPS Diluted
| -86.74 | -87.74 | -184.29 | -599.87 | -363.57 | -293 | -10 | -83 | 23 | -579 | -107 | 179 | 96 | -441 | 31 | 201 | 152.6 |
| EBITDA
| 2,642.388 | 77.951 | -1,318.486 | -1,414.117 | -4,164.023 | 803.622 | 2,262.91 | -713.653 | 3,026.139 | -913.229 | 121.14 | 6,883.035 | 5,090.687 | -2,105.803 | 2,916.586 | 4,741.604 | 3,741.219 |
| EBITDA Ratio
| 0.03 | 0.001 | -0.016 | -0.016 | -0.048 | 0.009 | 0.027 | -0.009 | 0.041 | -0.012 | 0.002 | 0.081 | 0.065 | -0.029 | 0.042 | 0.076 | 0.062 |